Assessment of the responsiveness of the Rasch-built, CIPN-specific questionnaire (CIPN-RODS) to clinical changes in patients undergoing neurotoxic chemotherapy. - Assessment of the CIPN-RODS in patients undergoing neurotoxic chemotherapy.

niversitair Medisch Centrum0 个研究点目标入组 5 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

Trial is onging in other countries

•1. Subjects must be candidates for chemotherapy including in the treatment plan platinum-based drugs or taxanes at doses expected to be potentially neurotoxic
•2. Male and female subjects who are 18 years of age or older.
•3. Subjects must give informed consent by signing and dating an informed consent form prior to study entry.
•4. Subjects must have a Karnofsky performance score greater than or equal to 70.

•1. Poor prognosis, with high probability to be unable to complete the planned chemotherapy treatment.
•2. Concomitant neurologic conditions, e.g., brain tumor, spinal or brain metastases.
•3. Severe depression that in the opinion of the Investigator would complicate the assessments.
•4. Chronic treatment with antiepileptic drugs, antidepressants and major analgesics, unless stable dosing and conditions have been reached for 3 months prior to entry.
•5. Subjects with a known presence of peripheral nerve damage due to another illness or medication.
•6. Subjects who are currently receiving another medication that has known potential to produce neurologic peripheral nerve toxicity (e.g. metrodiazole or isoniazid).

发起方

niversitair Medisch Centrum